UBS Group
PASW

UBS Group’s Ping An Biomedical PASW Stock Holding History

UBS Group’s Portfolio PASW Stock Details PASW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,239
Closed -$2.14K – 11480
2026
Q1 		$2.14K Buy
16,239
+11,515
+244% +$2.4K ﹤0.01% 9347
2025
Q4 		$2.37K Buy
4,724
+4,651
+6,371% +$3.1K ﹤0.01% 9324
2025
Q3 		$91 Buy
+73
New +$108 ﹤0.01% 9934

Other funds holding PASW

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

UBS Group's PASW Position: Q2 2026 in Review

UBS Group sold out of Ping An Biomedical (PASW) in Q2 2026, closing a stake of 16,239 shares — an estimated $2.14K sold.

UBS Group first reported a position in PASW in Q3 2025 and held it in 3 quarters. The position peaked at $2.37K in Q4 2025. 4 funds tracked by Wall St. Rank hold PASW as of Q2 2026.

  • UBS Group reported no remaining Ping An Biomedical position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 16,239 Ping An Biomedical shares in Q2 2026, an estimated $2.14K.
  • UBS Group first reported a position in Ping An Biomedical in Q3 2025 and held it in 3 quarters.
  • UBS Group's Ping An Biomedical position peaked at $2.37K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Ping An Biomedical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.